The impact of functional LIG4 polymorphism on platinum-based chemotherapy response and survival in non-small cell lung cancer

Medical Oncology

Volumn 31, Issue 5, 2014, Pages

  Jiang, You Hua ^a   Xu, Xiao Ling ^a   Ruan, Hai Hong ^b   Xu, Wei Zhen ^a   Li, Dan ^a   Feng, Jian Guo ^a   Han, Qian Bo ^a   Mao, Wei Min ^a  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b ZHEJIANG UNIVERSITY OF MEDIA AND COMMUNICATIONS   (China)

Author keywords

Chemotherapy response; LIG4 Thr9Ile; Non small cell lung cancer; Polymorphism

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; ISOLEUCINE; LIGASE; LIGASE 4; NIBRIN; PACLITAXEL; PEMETREXED; PLATINUM; RAD51 PROTEIN; THREONINE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHEMOSENSITIVITY; CHINESE; DNA REPAIR; FEMALE; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84898839868     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0959-7     Document Type: Article

References (28)

1. Yang L, Parkin DM, Li LD, Chen YD, Bray F. Estimation and projection of the national profile of cancer mortality in China: 1991-2005. Br J Cancer. 2004;90(11):2157-66. doi:10.1038/sj.bjc.6601813. (Pubitemid 38869723)
2. Bidoli P, Zilembo N, Cortinovis D, Mariani L, Isa L, Aitini E, Cullura D, Pari F, Nova P, Mancin M, Formisano B, Bajetta E. Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study. Ann Oncol. 2007;18(3):461-7. doi:10.1093/annonc/mdl415. (Pubitemid 46359623)
3. Vilmar A, Sorensen JB. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer. 2009;64(2):131-9. doi:10.1016/j.lungcan.2008.08.006.
4. Bunn PA Jr, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res. 1998;4(5):1087-100. (Pubitemid 28213318)
5. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, Lynch TJ, Neuberg DS, Christiani DC. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol. 2004;22(13):2594-601. doi:10.1200/JCO.2004.08.067. (Pubitemid 41103746)
6. Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, Lynch TJ, Su L, Christiani DC. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res. 2004;10(15): 4939-43. doi:10.1158/1078-0432.CCR-04-0247. (Pubitemid 39099767)
7. Johnson DH. Gemcitabine for the treatment of non-small-cell lung cancer. Oncology (Williston Park). 2001;15(3 Suppl 6):33-9. (Pubitemid 33739202)
8. Jordan P, Carmo-Fonseca M. Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci. 2000;57(8-9):1229-35. (Pubitemid 30663480)
9. van de Vaart PJ, Belderbos J, de Jong D, Sneeuw KC, Majoor D, Bartelink H, Begg AC. DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer. 2000;89(2):160-6. doi:10.1002/(SICI)1097-0215(20000320)89:2〈160:AID-IJC10〉3.0.CO;2-J. (Pubitemid 30185925)
10. Lu M, Lu J, Yang X, Yang M, Tan H, Yun B, Shi L. Association between the NBS1 E185Q polymorphism and cancer risk: a meta-analysis. BMC Cancer. 2009;9:124. doi:10.1186/1471-2407-9-124.
11. Yang T, Chang PY, Park SL, Bastani D, Chang SC, Morgenstern H, Tashkin DP, Mao JT, Papp JC, Rao JY, Cozen W, Mack TM, Greenland S, Zhang ZF. Tobacco smoking, NBS1 polymorphisms, and survival in lung and upper aerodigestive tract cancers with semi-Bayes adjustment for hazard ratio variation. Cancer Causes Control. 2014;25(1):11-23. doi:10.1007/s10552-013-0303-0.
12. Zheng J, Zhang C, Jiang L, You Y, Liu Y, Lu J, Zhou Y. Functional NBS1 polymorphism is associated with occurrence and advanced disease status of nasopharyngeal carcinoma. Mol Carcinog. 2011;50(9):689-96. doi:10.1002/mc.20803.
13. Yao F, Fang Y, Chen B, Jin F, Wang S. Association between the NBS1 Glu185Gln polymorphism and breast cancer risk: a metaanalysis. Tumour Biol. 2013;34(2):1255-62. doi:10.1007/s13277-013-0668-4.
14. Yu KD, Yang C, Fan L, Chen AX, Shao ZM. RAD51 135G>C does not modify breast cancer risk in non-BRCA1/2 mutation carriers: evidence from a meta-analysis of 12 studies. Breast Cancer Res Treat. 2011;126(2):365-71. doi:10.1007/s10549-010-0937-5.
15. Smolarz B, Samulak D, Michalska M, Goralczyk B, Szyllo K, Lewy J, Sporny S, Kokolaszwili G, Burzynski M, Romanowicz-Makowska H. 135G>C and 172G>T polymorphism in the 5' untranslated region of RAD51 and sporadic endometrial cancer risk in Polish women. Pol J Pathol. 2011;62(3):157-62.
16. Antoniou AC, Sinilnikova OM, Simard J, Leone M, Dumont M, Neuhausen SL, Struewing JP, Stoppa-Lyonnet D, Barjhoux L, Hughes DJ, Coupier I, Belotti M, Lasset C, Bonadona V, Bignon YJ, Rebbeck TR, Wagner T, Lynch HT, Domchek SM, Nathanson KL, Garber JE, Weitzel J, Narod SA, Tomlinson G, Olopade OI, Godwin A, Isaacs C, Jakubowska A, Lubinski J, Gronwald J, Gorski B, Byrski T, Huzarski T, Peock S, Cook M, Baynes C, Murray A, Rogers M, Daly PA, Dorkins H, Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Niederacher D, Deissler H, Spurdle AB, Chen X, Waddell N, Cloonan N, Kirchhoff T, Offit K, Friedman E, Kaufmann B, Laitman Y, Galore G, Rennert G, Lejbkowicz F, Raskin L, Andrulis IL, Ilyushik E, Ozcelik H, Devilee P, Vreeswijk MP, Greene MH, Prindiville SA, Osorio A, Benitez J, Zikan M, Szabo CI, Kilpivaara O, Nevanlinna H, Hamann U, Durocher F, Arason A, Couch FJ, Easton DF, Chenevix-Trench G. RAD51 135G->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet. 2007;81(6):1186-200. doi:10.1086/522611.
17. Sakiyama T, Kohno T, Mimaki S, Ohta T, Yanagitani N, Sobue T, Kunitoh H, Saito R, Shimizu K, Hirama C, Kimura J, Maeno G, Hirose H, Eguchi T, Saito D, Ohki M, Yokota J. Association of amino acid substitution polymorphisms in DNA repair genes TP53, POLI, REV1 and LIG4 with lung cancer risk. Int J Cancer. 2005;114(5):730-7. doi:10.1002/ijc.20790. (Pubitemid 40344434)
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205-16.
19. Figueroa JD, Malats N, Rothman N, Real FX, Silverman D, Kogevinas M, Chanock S, Yeager M, Welch R, Dosemeci M, Tardon A, Serra C, Carrato A, Garcia-Closas R, Castano-Vinyals G, Garcia-Closas M. Evaluation of genetic variation in the double-strand break repair pathway and bladder cancer risk. Carcinogenesis. 2007;28(8):1788-93. doi:10.1093/carcin/bgm132. (Pubitemid 47289043)
20. Yin M, Liao Z, Liu Z, Wang LE, O'Reilly M, Gomez D, Li M, Komaki R, Wei Q. Genetic variants of the nonhomologous end joining gene LIG4 and severe radiation pneumonitis in non-small cell lung cancer patients treated with definitive radiotherapy. Cancer. 2012;118(2):528-35. doi:10.1002/cncr.26214.
21. Mucha B, Przybylowska-Sygut K, Dziki L, Dziki A, Sygut A, Majsterek I. Lack of association between the 135G/C RAD51 gene polymorphism and the risk of colorectal cancer among Polish population. Pol Przegl Chir. 2012;84(7):358-62. doi:10.2478/v10035-012-0060-x.
22. Chen X, Sun H, Ren S, Kim Curran V, Zhang L, Zhou S, Zhang J, Zhou C. Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients. Clin Transl Oncol. 2012;14(3):207-13.
23. Cheng H, Sun N, Sun X, Chen B, Li F, Feng J, Cheng L, Cao Y. Polymorphisms in hMSH2 and hMLH1 and response to platinum-based chemotherapy in advanced non-small-cell lung cancer patients. Acta Biochim Biophys Sin (Shanghai). 2010;42(5):311-7.
24. Hu L, Wu C, Zhao X, Heist R, Su L, Zhao Y, Han B, Cao S, Chu M, Dai J, Dong J, Shu Y, Xu L, Chen Y, Wang Y, Lu F, Jiang Y, Yu D, Chen H, Tan W, Ma H, Chen J, Jin G, Wu T, Lu D, Christiani DC, Lin D, Hu Z, Shen H. Genome-wide association study of prognosis in advanced non-small cell lung cancer patients receiving platinum-based chemotherapy. Clin Cancer Res. 2012;18(19):5507-14. doi:10.1158/1078-0432.CCR-12-1202.
25. Huang RS, Johnatty SE, Gamazon ER, Im HK, Ziliak D, Duan S, Zhang W, Kistner EO, Chen P, Beesley J, Mi S, O'Donnell PH, Fraiman YS, Das S, Cox NJ, Lu Y, Macgregor S, Goode EL, Vierkant RA, Fridley BL, Hogdall E, Kjaer SK, Jensen A, Moysich KB, Grasela M, Odunsi K, Brown R, Paul J, Lambrechts D, Despierre E, Vergote I, Gross J, Karlan BY, Defazio A, Chenevix-Trench G, Dolan ME. Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res. 2011;17(16):5490-500. doi:10.1158/1078-0432.CCR-11-0724.
26. Tauchi H. Positional cloning and functional analysis of the gene responsible for Nijmegen breakage syndrome, NBS1. J Radiat Res. 2000;41(1):9-17.
27. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92-8. doi:10.1056/ NEJMoa011954. (Pubitemid 34438899)
28. Kelly K, Crowley J, Bunn PA Jr, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001;19(13):3210-8. (Pubitemid 32591438)